Fisetin for Femoroacetabular Impingement
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing if Fisetin, which removes old, damaged cells, can help patients with hip issues heal better after surgery by reducing inflammation.
Who Is on the Research Team?
Johnny L Huard, PhD
Principal Investigator
Steadman Philippon Research Institute
Are You a Good Fit for This Trial?
Adults aged 18-80 with femoroacetabular impingement (FAI) or a hip labral tear, who can consent and follow study procedures. They must be scheduled for hip arthroscopy but cannot have had previous significant hip surgeries, systemic autoimmune diseases, uncontrolled diabetes, recent use of certain drugs like warfarin or senolytic agents, or conditions that could interfere with the trial.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Pre-operative Treatment
Participants receive 20mg/kg of Fisetin or placebo per day for 2 days prior to surgery
Surgery and Immediate Post-operative Care
Participants undergo hip arthroscopy with intra-operative PRP injection and post-operative losartan administration
Post-operative Treatment
Participants receive 20mg/kg of Fisetin or placebo on days 33, 34, 63, 64, 93, and 94 post-surgery
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Fisetin
- Placebo
Find a Clinic Near You
Who Is Running the Clinical Trial?
Steadman Philippon Research Institute
Lead Sponsor
United States Department of Defense
Collaborator